Despite the success of this therapeutic treatment, naked trastuzumab targeting of HER-2 expression in breast cancer is rarely curative by itself, and most of the effects of this drug are achieved in combination with chemotherapy [4–7]. Here, ERBB2 is linked to breast cancer.